<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pharvaris Bv — News on 6ix</title>
    <link>https://6ix.com/company/pharvaris-bv</link>
    <description>Latest news and press releases for Pharvaris Bv on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 10:50:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/pharvaris-bv" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835acc878dffbe2df10e243.webp</url>
      <title>Pharvaris Bv</title>
      <link>https://6ix.com/company/pharvaris-bv</link>
    </image>
    <item>
      <title>Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference</title>
      <link>https://6ix.com/company/pharvaris-bv/news/evidence-supporting-combined-use-of-deucrictibant-ir-with-deucrictibant-xr-presented-at-ciic-spring-2026-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/evidence-supporting-combined-use-of-deucrictibant-ir-with-deucrictibant-xr-presented-at-ciic-spring-2026-conference</guid>
      <pubDate>Mon, 20 Apr 2026 10:50:00 GMT</pubDate>
      <description>ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release (IR) capsule(s) in combination with deucrictiban</description>
    </item>
    <item>
      <title>Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-18</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-18</guid>
      <pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
      <description>Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline</description>
    </item>
    <item>
      <title>Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy &amp; Immunology</title>
      <link>https://6ix.com/company/pharvaris-bv/news/validation-of-patient-reported-outcomes-in-the-on-demand-treatment-of-hereditary-angioedema-attacks-published-in-clinical-reviews-in-allergy-and-immunology</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/validation-of-patient-reported-outcomes-in-the-on-demand-treatment-of-hereditary-angioedema-attacks-published-in-clinical-reviews-in-allergy-and-immunology</guid>
      <pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
      <description>Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms,</description>
    </item>
    <item>
      <title>Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026</title>
      <link>https://6ix.com/company/pharvaris-bv/news/deucrictibant-data-supporting-potentially-differentiated-profile-for-the-on-demand-and-prophylactic-treatment-of-bradykinin-mediated-angioedema-presented-at-aaaai-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/deucrictibant-data-supporting-potentially-differentiated-profile-for-the-on-demand-and-prophylactic-treatment-of-bradykinin-mediated-angioedema-presented-at-aaaai-2026</guid>
      <pubDate>Mon, 02 Mar 2026 11:50:00 GMT</pubDate>
      <description>RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE attacksFinal CHAPTER-1 data provide further evidence on long-term safety and efficacy of deucrictibant for the prevention of HAE attacks; single-dose, sustained therapeutic exposure with deucrictibant exten</description>
    </item>
    <item>
      <title>Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-present-clinical-data-aaaai-115000402</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-present-clinical-data-aaaai-115000402</guid>
      <pubDate>Tue, 10 Feb 2026 11:50:00 GMT</pubDate>
      <description>Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first timeZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the</description>
    </item>
    <item>
      <title>Pharvaris Outlines 2026 Strategic Priorities</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-outlines-2026-strategic-priorities-115000100</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-outlines-2026-strategic-priorities-115000100</guid>
      <pubDate>Mon, 12 Jan 2026 11:50:00 GMT</pubDate>
      <description>Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksEstimated cash runway into 1H2027 ZUG, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: P</description>
    </item>
    <item>
      <title>Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-positive-topline-data-rapide-3-pivotal-study-confirming-potential</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-positive-topline-data-rapide-3-pivotal-study-confirming-potential</guid>
      <pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
      <description>Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo</description>
    </item>
    <item>
      <title>Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in</description>
    </item>
    <item>
      <title>Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting</title>
      <link>https://6ix.com/company/pharvaris-bv/news/data-supporting-potentially-differentiated-pharvaris-portfolio-presented-acaai-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/data-supporting-potentially-differentiated-pharvaris-portfolio-presented-acaai-2025</guid>
      <pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
      <description>Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin</description>
    </item>
    <item>
      <title>Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-present-clinical-data-acaai-2025-annual-scientific-meeting-2025-10-23</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-present-clinical-data-acaai-2025-annual-scientific-meeting-2025-10-23</guid>
      <pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2</description>
    </item>
    <item>
      <title>Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-reports-second-quarter-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-reports-second-quarter-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
      <description>Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in</description>
    </item>
    <item>
      <title>Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-closing-2012-million-upsized-public-offering-ordinary-shares-and</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-closing-2012-million-upsized-public-offering-ordinary-shares-and</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral</description>
    </item>
    <item>
      <title>Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-pricing-upsized-175-million-public-offering-ordinary-shares-and</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-pricing-upsized-175-million-public-offering-ordinary-shares-and</guid>
      <pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral</description>
    </item>
    <item>
      <title>Pharvaris Announces Proposed Public Offering of Ordinary Shares</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-proposed-public-offering-ordinary-shares-2025-07-22</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-proposed-public-offering-ordinary-shares-2025-07-22</guid>
      <pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral</description>
    </item>
    <item>
      <title>Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-updates-timing-topline-data-announcement-rapide-3-pivotal-phase-3-study</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-updates-timing-topline-data-announcement-rapide-3-pivotal-phase-3-study</guid>
      <pubDate>Thu, 10 Jul 2025 04:00:00 GMT</pubDate>
      <description>Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 ZUG, Switzerland, July 10, 2025</description>
    </item>
    <item>
      <title>Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-treatment-hae-be</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-clinical-trial-data-highlighting-deucrictibant-treatment-hae-be</guid>
      <pubDate>Fri, 27 Jun 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2</description>
    </item>
    <item>
      <title>Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-presents-data-highlighting-potential-deucrictibant-prevent-and-treat</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-presents-data-highlighting-potential-deucrictibant-prevent-and-treat</guid>
      <pubDate>Mon, 16 Jun 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2</description>
    </item>
    <item>
      <title>Pharvaris Announces Annual Meeting of Shareholders</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-annual-meeting-shareholders-2025-06-10</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-announces-annual-meeting-shareholders-2025-06-10</guid>
      <pubDate>Tue, 10 Jun 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2</description>
    </item>
    <item>
      <title>Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-presents-data-supporting-ongoing-clinical-development-deucrictibant</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-presents-data-supporting-ongoing-clinical-development-deucrictibant</guid>
      <pubDate>Mon, 02 Jun 2025 04:00:00 GMT</pubDate>
      <description>Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treatedFirst-ever bradykinin B2 receptor</description>
    </item>
    <item>
      <title>Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses</title>
      <link>https://6ix.com/company/pharvaris-bv/news/pharvaris-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-upcoming</link>
      <guid isPermaLink="true">https://6ix.com/company/pharvaris-bv/news/pharvaris-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-upcoming</guid>
      <pubDate>Mon, 19 May 2025 04:00:00 GMT</pubDate>
      <description>ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2</description>
    </item>
  </channel>
</rss>